Research ExplorerPublicationsEsophageal metastasis from papillary thyroid cancer: diagnos...

Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT

Standard

Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT. / Wisotzki, Christian; Friese, Michael; Ehresmann, Jörg; Derlin, Thorsten.

In: CLIN NUCL MED, Vol. 39, No. 1, 01.01.2014, p. e73-4.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wisotzki, C, Friese, M, Ehresmann, J & Derlin, T 2014, 'Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT', CLIN NUCL MED, vol. 39, no. 1, pp. e73-4. https://doi.org/10.1097/RLU.0b013e3182816303

APA

Wisotzki, C., Friese, M., Ehresmann, J., & Derlin, T. (2014). Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT. CLIN NUCL MED, 39(1), e73-4. https://doi.org/10.1097/RLU.0b013e3182816303

Vancouver

Wisotzki C, Friese M, Ehresmann J, Derlin T. Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT. CLIN NUCL MED. 2014 Jan 1;39(1):e73-4. https://doi.org/10.1097/RLU.0b013e3182816303

Bibtex

@article{4ba6d44d763746149fad1a900851ae71,
title = "Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT",
abstract = "We report a case of esophageal metastasis from papillary thyroid cancer diagnosed by I SPECT/CT. A 70-year-old man presented with increasing thyroglobulin levels 13 years after thyroidectomy and ablation with I for thyroid cancer. The whole-body radioiodine scan demonstrated marked tracer uptake in the mediastinum, and SPECT/CT could clearly localize the activity to the esophagus. Subsequent surgical resection with histopathologic evaluation revealed an esophageal metastasis from papillary thyroid cancer. I SPECT/CT is a valuable tool for evaluation and precise anatomical localization of the foci of radionuclide activity in thyroid cancer, enabling adequate treatment.",
author = "Christian Wisotzki and Michael Friese and J{\"o}rg Ehresmann and Thorsten Derlin",
year = "2014",
month = jan,
day = "1",
doi = "10.1097/RLU.0b013e3182816303",
language = "English",
volume = "39",
pages = "e73--4",
journal = "CLIN NUCL MED",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Esophageal metastasis from papillary thyroid cancer: diagnosis by 131I SPECT/CT

AU - Wisotzki, Christian

AU - Friese, Michael

AU - Ehresmann, Jörg

AU - Derlin, Thorsten

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We report a case of esophageal metastasis from papillary thyroid cancer diagnosed by I SPECT/CT. A 70-year-old man presented with increasing thyroglobulin levels 13 years after thyroidectomy and ablation with I for thyroid cancer. The whole-body radioiodine scan demonstrated marked tracer uptake in the mediastinum, and SPECT/CT could clearly localize the activity to the esophagus. Subsequent surgical resection with histopathologic evaluation revealed an esophageal metastasis from papillary thyroid cancer. I SPECT/CT is a valuable tool for evaluation and precise anatomical localization of the foci of radionuclide activity in thyroid cancer, enabling adequate treatment.

AB - We report a case of esophageal metastasis from papillary thyroid cancer diagnosed by I SPECT/CT. A 70-year-old man presented with increasing thyroglobulin levels 13 years after thyroidectomy and ablation with I for thyroid cancer. The whole-body radioiodine scan demonstrated marked tracer uptake in the mediastinum, and SPECT/CT could clearly localize the activity to the esophagus. Subsequent surgical resection with histopathologic evaluation revealed an esophageal metastasis from papillary thyroid cancer. I SPECT/CT is a valuable tool for evaluation and precise anatomical localization of the foci of radionuclide activity in thyroid cancer, enabling adequate treatment.

U2 - 10.1097/RLU.0b013e3182816303

DO - 10.1097/RLU.0b013e3182816303

M3 - SCORING: Journal article

C2 - 23455522

VL - 39

SP - e73-4

JO - CLIN NUCL MED

JF - CLIN NUCL MED

SN - 0363-9762

IS - 1

ER -